Bipolar Disorder (Manic Depression) – Pipeline Review, H1 2012

Introduction

Global Markets Direct’s, 'Bipolar Disorder (Manic Depression) - Pipeline Review, H1 2012', provides an overview of the Bipolar Disorder (Manic Depression) therapeutic pipeline. This report provides information on the therapeutic development for Bipolar Disorder (Manic Depression), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bipolar Disorder (Manic Depression). 'Bipolar Disorder (Manic Depression) - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Bipolar Disorder (Manic Depression).
- A review of the Bipolar Disorder (Manic Depression) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Bipolar Disorder (Manic Depression) pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Highlights

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Bipolar Disorder (Manic Depression).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Bipolar Disorder (Manic Depression) pipeline depth and focus of Bipolar Disorder (Manic Depression) therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
[Studien Infos ausblenden]

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Bipolar Disorder (Manic Depression) Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Bipolar Disorder (Manic Depression) 9
Bipolar Disorder (Manic Depression) Therapeutics under Development by Companies 11
Bipolar Disorder (Manic Depression) Therapeutics under Investigation by Universities/Institutes 13
Late Stage Products 15
Comparative Analysis 15
Mid Clinical Stage Products 16
Comparative Analysis 16
Early Clinical Stage Products 17
Comparative Analysis 17
Discovery and Pre-Clinical Stage Products 18
Comparative Analysis 18
Bipolar Disorder (Manic Depression) Therapeutics – Products under Development by Companies 19
Bipolar Disorder (Manic Depression) Therapeutics – Products under Investigation by Universities/Institutes 20
Companies Involved in Bipolar Disorder (Manic Depression) Therapeutics Development 21
DURECT Corporation 21
AstraZeneca PLC 22
Eli Lilly and Company 23
Dainippon Sumitomo Pharma Co., Ltd. 24
Alexza Pharmaceuticals, Inc. 25
Astellas Pharma Inc. 26
Cephalon, Inc. 27
Gedeon Richter Plc. 28
IntelGenx Technologies Corp. 29
Jazz Pharmaceuticals, Inc. 30
Repligen Corporation 31
Biotie Therapies Corp. 32
D-Pharm Ltd. 33
Omeros Corporation 34
Marinus Pharmaceuticals, Inc. 35
KemPharm, Inc. 36
Naurex, Inc. 37
Bipolar Disorder (Manic Depression) – Therapeutics Assessment 38
Assessment by Monotherapy Products 38
Assessment by Combination Products 39
Assessment by Route of Administration 40
Assessment by Molecule Type 42
Drug Profiles 44
Nuvigil - Drug Profile 44
Latuda - Drug Profile 46
FK949E - Drug Profile 48
Cariprazine - Drug Profile 49
SYN-111 - Drug Profile 50
RG2417 - Drug Profile 52
Adasuve - Drug Profile 53
JZP-4 - Drug Profile 55
KP303 - Drug Profile 56
Taurine - Drug Profile 57
Riluzole - Drug Profile 58
DP-VPA - Drug Profile 59
RU-486 - Drug Profile 61
Acetyl-L-Carnitine + Alpha-Lipoic Acid - Drug Profile 62
Valacyclovir - Drug Profile 64
Seroquel XR + Pramipexole - Drug Profile 65
Lisdexamfetamine - Drug Profile 66
Rilutek - Drug Profile 67
Mirapex - Drug Profile 69
Ketamine - Drug Profile 70
Scopolamine - Drug Profile 71
Celexa - Drug Profile 72
Lamotrigine + Antidepressant Therapy - Drug Profile 73
Recombinant Human Erythropoietin - Drug Profile 74
Ceftriaxone - Drug Profile 75
Tamoxifen - Drug Profile 76
Provera - Drug Profile 78
Digibind - Drug Profile 79
Chelerythrine - Drug Profile 80
Valproate + Risperidone - Drug Profile 81
Naltrexone + Valproate - Drug Profile 82
Liothyronine - Drug Profile 83
Sertraline + Lithium Carbonate - Drug Profile 84
Oral Uridine - Drug Profile 86
Abilify - Drug Profile 87
Quetiapine XR - Drug Profile 88
Mifepristone - Drug Profile 89
Divalproex ER - Drug Profile 90
Lamictal - Drug Profile 91
LY2979165 - Drug Profile 92
AZD4451 - Drug Profile 93
Quetiapine - Drug Profile 94
Valproate + Memantine - Drug Profile 95
INT0022 - Drug Profile 96
Latuda + Lithium - Drug Profile 97
NP03 - Drug Profile 99
NRX-1050 Series - Drug Profile 101
Relday - Drug Profile 102
GPR78 Antagonist - Drug Profile 103
Bipolar Disorder (Manic Depression) Therapeutics – Drug Profile Updates 104
Bipolar Disorder (Manic Depression) Therapeutics – Discontinued Products 111
Bipolar Disorder (Manic Depression) Therapeutics - Dormant Products 112
Bipolar Disorder (Manic Depression) – Product Development Milestones 114
Featured News & Press Releases 114
Appendix 120
Methodology 120
Coverage 120
Secondary Research 120
Primary Research 120
Expert Panel Validation 121
Contact Us 121
Disclaimer 121
[Inhaltsverzeichnis ausblenden]

List of Tables
Number of Products Under Development for Bipolar Disorder (Manic Depression), H1 2012 12
Products under Development for Bipolar Disorder (Manic Depression) – Comparative Analysis, H1 2012 13
Number of Products under Development by Companies, H1 2012 15
Number of Products under Investigation by Universities/Institutes, H1 2012 17
Comparative Analysis by Late Stage Development, H1 2012 18
Comparative Analysis by Mid Clinical Stage Development, H1 2012 19
Comparative Analysis by Early Clinical Stage Development, H1 2012 20
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012 21
Products under Development by Companies, H1 2012 22
Products under Investigation by Universities/Institutes, H1 2012 23
DURECT Corporation, H1 2012 24
AstraZeneca PLC, H1 2012 25
Eli Lilly and Company, H1 2012 26
Dainippon Sumitomo Pharma Co., Ltd., H1 2012 27
Alexza Pharmaceuticals, Inc., H1 2012 28
Astellas Pharma Inc., H1 2012 29
Cephalon, Inc., H1 2012 30
Gedeon Richter Plc., H1 2012 31
IntelGenx Technologies Corp., H1 2012 32
Jazz Pharmaceuticals, Inc., H1 2012 33
Repligen Corporation, H1 2012 34
Biotie Therapies Corp., H1 2012 35
D-Pharm Ltd., H1 2012 36
Omeros Corporation, H1 2012 37
Marinus Pharmaceuticals, Inc., H1 2012 38
KemPharm, Inc., H1 2012 39
Naurex, Inc., H1 2012 40
Assessment by Monotherapy Products, H1 2012 41
Assessment by Combination Products, H1 2012 42
Assessment by Stage and Route of Administration, H1 2012 44
Assessment by Stage and Molecule Type, H1 2012 46
Bipolar Disorder (Manic Depression) Therapeutics – Drug Profile Updates 107
Bipolar Disorder (Manic Depression) Therapeutics – Discontinued Products 114
Bipolar Disorder (Manic Depression) Therapeutics – Dormant Products 115
List of Figures
Number of Products under Development for Bipolar Disorder (Manic Depression), H1 2012 12
Products under Development for Bipolar Disorder (Manic Depression) – Comparative Analysis, H1 2012 13
Products under Development by Companies, H1 2012 14
Products under Investigation by Universities/Institutes, H1 2012 16
Late Stage Products, H1 2012 18
Mid Clinical Stage Products, H1 2012 19
Early Clinical Stage Products, H1 2012 20
Discovery and Pre-Clinical Stage Products, H1 2012 21
Assessment by Monotherapy Products, H1 2012 41
Assessment by Combination Products, H1 2012 42
Assessment by Route of Administration, H1 2012 43
Assessment by Stage and Route of Administration, H1 2012 44
Assessment by Molecule Type, H1 2012 45
Assessment by Stage and Molecule Type, H1 2012 46
[Tabellenverzeichnis ausblenden]